CAS 635-39-2: 6H-Purin-6-one, 2-amino-1,9-dihydro-, hydrochloride (1:1)

Guanine hydrochloride hydrate is a guanine-based nucleoside analogue that inhibits the synthesis of DNA and RNA. It has been used in the treatment of leukemia and myelodysplastic syndrome. Guanine hydrochloride hydrate binds to the enzyme thioguanine synthase, which converts guanine into thioguanine, thereby preventing its conversion into other nucleotide analogues. The binding of Guanine hydrochloride hydrate to thioguanine synthase is reversible, making this drug an attractive therapeutic option for treating hematological malignancies.

Guanine hydrochloride

Guanine HCl is a nitrogen-containing heterocyclic molecule that is an important component of DNA. The human body produces guanine as a byproduct of nucleic acid metabolism, so it can be found in the blood, urine, and other tissues. Guanine HCl has been used in vitro to diagnose leukemia, lymphoma, and other cancers. It is also used to study the metabolic rate of cells and tissues under different conditions. When guanine HCl is protonated, it has a distinctive fluorescence spectrum with peaks at around 390 nm and 410 nm that can be measured using fluorescence spectrometry. The major metabolite of guanine HCl is thioguanine (TG), which can be detected using monoclonal antibody tests or by measuring malonic acid levels in serum samples.